Take stock of where we stand in the EU on falsified medicines and paint the landscape of the global issue
Falsified medicines are a major threat to public health. As falsifications become more sophisticated, the risk that falsified medicines reach patients in the EU increases every year.
To counteract this in the EU the European Council and European Parliament have taken certain legal measures such as the Falsified Medicines Directive (Directive 2011/62/EU) publish on 1 July 2011 and coming into effect on 2 January 2013. This called for the introduction to the following measured:
- Obligatory safety features on the outer packaging of the medicines, to be detailed via a delegated act;
- A common, EU-wide logo to identify legal online pharmacies. This would make it easier to distinguish between legal and illegal online pharmacies throughout the European Union;
- Tougher rules on the controls and inspections of producers of active pharmaceutical ingredients; and
- Strengthened record-keeping requirements for wholesale distributors
This conference covers:
- The current situation in the EU on falsified medicines
- How the national agencies have worked on this
- How the stakeholders such as industry, patients, pharmacies, distributers have worked together
- Key issues via focused workshops.
Attend this essential conference to hear from key speakers who will present the approaches of the Member States on the implementation of the new legislation, and the impact and achievements of the concerned stakeholders such as industry, patients, pharmacies and distributors who have worked independently and together to find solutions.
Preliminary programme* includes
Key Note: How the Issue of Falsified Medicines has Evolved and what are the Global Implications?
Developments Within Europe and who are Affected
Session 1 – The views from the European Commission and Member States, including Belgium, Luxembourg, Spain and the UK. Topics include serialization, data protection, national reimbursement systems and IT systems or unique identifiers linked to those.
Session 2 Panel discussion with various stakeholders in the supply chain, including innovator industry, community and hospital pharmacists, generic and biosimilar industry and patients, to discuss the implementation on each part of the chain.
Speakers include
• Hugo Bonar, Enforcement Manager, Health Products Regulatory Authority, Ireland
• Patrizia Tosetti, Policy Officer, European Commission
• Marcin Wisniewski, Pharmacy Inspector, Ministry of Health, Luxembourg
• Belén Escribano, Head of Department, Pharmaceutical Inspection and Enforcement Department, AEMPS, Spain
• Gerald Heddell, Director, Inspection Enforcement & Standards Division, MHRA, UK
• François-Xavier Lery, Head of Section for Pharmaceutical Care, Consumer Health Protection and Anti-Counterfeiting, European Directorate of Quality of Medicines & Healthcare, France
• Maarten Van Baelen, Director, Medicines for Europe, Belgium
• Tania Snioch, Director, Healthcare, GS1, Belgium
*subject to change
Click here to view more information and a preliminary programme.
To register, please log in or create an account
Course Price (£) (including VAT):
Industry fee: £665.50
Government fee: £332.75
Academic fee: £332.75
Student fee: £114.95
All fees are shown in Pounds Sterling and include VAT - Fee excludes accommodation and travel.
- The delegate ticket includes refreshments at coffee breaks and buffet lunches (if applicable).
- All cancellations must be received in writing 28 calendar days before the start of the course and will be subject to an administration fee of £100 + GB VAT. We regret that registrations cannot be transferred to another course, however delegate substitutions may be made up to 10 working days before the course.